Until March 2017 doing business as Aerpio Therapeutics, Aerpio Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The company's therapeutics are based on Tie2 activation and the stabilization of hypoxia-inducible factor 1?. The Companys lead program, AKB-9778, is a first in class small molecule stabilizer of the Tie2 pathway that effectively blocks vascular leak and pathologic angiogenesis in multiple disease conditions, initially being developed for the treatment of diabetic macular edema. The lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor ? (HIF-?) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie2 program, AKB-9778, recently completed a proof-of-concept, Phase 2a study (TIME-2). AKB-4924, the lead compound in our HIF-? stabilization program, has recently completed a Phase 1a study.
